Temporal trends in the pre-procedural TIMI flow grade among patients with ST-segment elevation myocardial infarction – From the ACSIS registry

Nili Schamroth Pravda, Tal Cohen, Robert Klempfner, Ran Kornowski, Roy Beigel, Katia Orvin, Merry Abitbol, Miri Schamroth Pravda, Idit Dobrecky-Mery, Ronen Rubinshtein, Madji Saada, Alon Eisen

1. Introduction

Thrombolysis in Myocardial Infarction (TIMI) coronary grade flow is an established, validated score to assess the epicardial perfusion on coronary angiography. TIMI flow grade 0 represents total occlusion, while TIMI flow grade 3 represents normal epicardial perfusion [1]. Previous studies have demonstrated that patients with low grade TIMI flow prior to percutaneous coronary intervention (PCI) have a less favorable outcome. Preprocedural TIMI flow has been found to be an independent predictor of survival in patients with acute myocardial infarction [2,3] and has also been shown to predict final infarct size [4]. Over the years there has been marked advancement in the management of patients presenting with STEMI in the areas of pre-hospital management, pharmacological therapy and procedural techniques. However, there is conflicting evidence if these advances have translated into improved clinical outcomes [5,6]. We aimed to assess the temporal trends in preprocedural TIMI flow grade among patients presenting...
with STEMI and to examine whether TIMI flow grade is associated with clinical outcomes and remains a significant prognostic factor in the current era.

2. Methods

The current study included consecutive patients from the acute coronary syndrome (ACS) Israeli Surveys (ACISIS) between 2008 and 2018, who presented with STEMI and had data on the initial TIMI grade prior to revascularization. The ACISIS registry is a prospective survey conducted every 2–3 years that enrolls consecutive patients from all 26 coronary care units operating in Israel over a 2-month period. The data is entered electronically by dedicated and specifically trained research personnel. Informed consent is obtained by all patients. The pre-specified demographic, cardiovascular risk factors, co-morbidities, medications and clinical data were recorded along with admission and discharge diagnoses as defined by the attending physicians based on clinical, electrocardiographic, and biochemical criteria. The institutional review board (IRB) of all the participating hospitals approved the survey, which was performed in accordance with the Helsinki declaration. Preprocedural TIMI coronary grade flow was determined by the treating physician at the time of angiography (TIMI flow grade 0, 1, 2, or 3). Patients’ management was at the discretion of the attending physicians. A time-dependent analysis of patients with TIMI flow grade 0 versus TIMI flow grade 1–3 was performed. Survey years were divided according to the time periods of the index ACS event: early (2008–2010) and late period (2013–2018). Clinical outcomes included in-hospital complications, 30-day major adverse cardiovascular events (MACE), and 1-year all-cause mortality. In-hospital complications were a composite of congestive heart failure, hemodynamically significant right ventricular infarction (RVI), recurrent myocardial infarction (MI), stent thrombosis, ventricular septal defect, ≥ moderate mitral regurgitation, pericarditis, ventricular arrhythmia, new onset atrial fibrillation, bradycardia/asystole, cerebrovascular event and acute renal failure. 30-day MACE was comprised of all-cause mortality, MI, stroke, unstable angina, stent thrombosis and urgent revascularization. Data regarding the outcomes were determined by hospital chart review, telephone contact, clinical follow-up and by matching identification numbers of patients with the Israeli National Population Registry (for 30-day and 1-year mortality).

3. Statistical Methods

Patients characteristics are presented as mean (SD) or median (IQR) as appropriate for normal/non-normal distributed continuous variables, and as frequency (%) for categorical variables. The study groups were tested with chi-square for categorical variables and with t-test or Mann Whitney Wilcoxon test as appropriate for normal/non-normal distributed continuous variables. The Kaplan-Meier log rank test was used to test the variable of interest on survival. All tests were conducted at a two sided overall 5% significance level (alpha = 0.05).

4. Results

Of the 3840 patients presenting with STEMI and who underwent primary PCI, included were 2453 patients for whom data regarding TIMI flow prior to revascularization was available. There were 934 (38.1%) patients in the early period and 1519 (61.9%) patients in the late period. The distribution of preprocedural TIMI flow grades in the early and late periods is depicted in Fig. 1. The majority of patients presenting with STEMI had TIMI flow 0 (58.9% in the early period and 58.7% in the late period, $P = 0.97$).

In the late period, there were more patients with STEMI presenting with TIMI flow 3 compared to the earlier period (18.6% vs 14.5%, $P = 0.01$). Baseline characteristics are depicted in Table 1 and Table S1. Demographic data was similar between those with TIMI flow 0 and TIMI flow 1–3. The median age of the patients was 60 years, and the majority were male (82.2% vs 83.6%, $P = 0.39$). Comorbidities, such as dyslipidemia were highly prevalent in both groups (67.7% vs 64.8%, $P = 0.15$), as well as increased BMI (27.1 vs 26.8, $P = 0.12$) and almost a quarter of the patients had a prior MI (24.0% vs 21.1%, $P = 0.11$). Prior use of medications such as angiotensin receptor blockers (ARBs) and beta blockers was more prevalent in those presenting with TIMI 0 than those with TIMI 1–3. Over time, among patients with TIMI 0, cardiovascular risk-factors were similar. Among those with TIMI 1–3, the prevalence of hypertension and diabetes increased significantly (46.3% vs. 54.3%, $P = 0.12$, and 33.2% vs 25.6%, $P = 0.01$, in the early and late periods, respectively). Over time there was also a significant increase in the use of ARBs, statins and hypoglycemic agents in both those presenting with TIMI 0 as well as in those presenting with TIMI 1–3.

Patients’ vital signs on first medical contact are shown in Table 2 and Table S2. Time from symptom onset to primary PCI in patients with TIMI 0 was similar to patients with TIMI 1–3 (184.0 min vs 194.5 min, $P = 0.13$). This did not significantly change over time. Table 3 and Table S3 show the angiography, in-hospital complications and laboratory results. Patients presenting with TIMI 0 were significantly more likely to have an in-hospital complication compared with TIMI 1–3 (30.3% vs 21.5%, $P < 0.001$), including cardiogenic shock (6.3% vs 3.7%, $P = 0.005$), hemodynamically significant RVI (2.8% vs 0.7%, $P < 0.001$), as well as arrhythmic complications such as ventricular tachycardia (2.6% vs 0.6%, $P < 0.001$), new atrial fibrillation (7.1% vs 4.1%, $P = 0.002$), high degree atrioventricular block (4.1% vs 2.3%, $P = 0.019$) and asystole (3.1% vs 1.4%, $P = 0.009$). Over time, there was a significant increase in the use of drug eluting stents and a decrease in the use of bare metal stents. Over time, there was a significantly lower rate of in-hospital complications in those presenting with TIMI 0 (36.1% in the early period vs. 26.8% in the late period, $P < 0.001$), mainly driven by less patients presenting with Killip class 2–3, RVI, and some arrhythmias. This difference over time periods was not observed in those presenting with TIMI 1–3 in whom the rate of in-hospital complications remained unchanged. Patients with TIMI 0 had a significantly higher rate of acute renal failure and a higher biomarker rise compared to those presenting with TIMI 1–3. Table 4 and S4 details the treatment at discharge of the patients. There was no significant difference between the treatment prescribed to those presenting with TIMI 0 vs TIMI 1–3. Regardless of the initial TIMI flow, the majority of patients were discharged with clopidogrel in the early period and with newer P2Y12 inhibitor agents in the late period. Over time, significantly more patients were discharged with statins and ACE-I (Angiotensin-converting-enzyme inhibitors) /ARBs regardless of initial TIMI score, and more patients were referred for cardiac rehabilitation on discharge in the late period.

Overall patients presenting with TIMI 0 had worse clinical outcomes compared with those presenting with TIMI 1–3. This was evident both for 30-d MACE (12.3% vs 6.9%, $P < 0.001$), as well as for 1 year mortality (8.4% vs 4.5%, $P < 0.001$) (Table S5). Fig. 2 shows the Kaplan Meier curve for time to mortality demonstrating significantly poorer survival for those with TIMI 0 compared to those presenting with TIMI 1–3, both in the early and late period. Over time, those with TIMI 0 did not have a significant decrease in 30-d MACE or 1 year mortality. However, the rate of recurrent MI significantly decreased in the late period (2.7% vs 0.7%, $P = 0.005$) as seen in Table 5. The 1-year mortality of both those presenting with TIMI 0 and TIMI 1–3 did not change between periods (Table S5).
5. Discussion

This study based on a national ACS registry, demonstrates important insights regarding the prognostic value of the preprocedural TIMI flow grade in a real-world cohort of patients presenting with STEMI. Firstly, the majority of patients presenting with STEMI have TIMI flow grade 0. The proportion of patients with TIMI flow 0 has remained unchanged while the proportion of those with TIMI flow 3 has increased in the later period. Secondly, despite advances in PCI and pharmacotherapy, those presenting with TIMI flow 0 still have poorer early clinical outcomes compared to those with TIMI flow 1-3. However, the rate of in-hospital complications of patients with TIMI flow 0 has decreased over time, while it remained unchanged in patients with TIMI 1-3. Thirdly, the 30d MACE and 1-year mortality have not significantly changed over time in either subgroup of TIMI flow grade 0 or 1-3.

Table 1
Baseline Characteristics over the time periods of those with TIMI 0 vs TIMI 1-3.

|            | TIMI 0          | TIMI 1-3         |
|------------|-----------------|------------------|
|            | 2008–2010       | 2013–2018        | 2008–2010       | 2013–2018        | p value |
| n          | 550             | 892              | 384             | 627              |
| Baseline characteristics |                   |                   |                  |                  |
| Age, years (median [IQR]) | 59.00 [52.00, 69.00] | 60.00 [53.00, 69.00] | 0.40            | 58.00 [51.00, 68.00] | 60.00 [52.00, 71.00] | 0.06 |
| Gender (male) | 449 (81.6)      | 736 (82.5)       | 0.72            | 323 (84.1)       | 522 (83.3)         | 0.78 |
| Dyslipidemia | 375 (68.8)      | 594 (67.0)       | 0.52            | 257 (67.1)       | 394 (63.4)         | 0.26 |
| Hypertension | 290 (53.0)      | 486 (54.7)       | 0.57            | 177 (46.3)       | 338 (54.3)         | 0.01 |
| Current smokers | 268 (49.0)    | 463 (51.9)       | 0.30            | 197 (51.8)       | 295 (47.0)         | 0.15 |
| Diabetes mellitus | 161 (29.3)   | 278 (31.2)       | 0.48            | 98 (25.6)        | 207 (32.2)         | 0.01 |
| Family history of CAD | 167 (31.7)  | 261 (33.2)       | 0.61            | 123 (33.3)       | 188 (34.6)         | 0.74 |
| BMI (kg/m2), (median [IQR]) | 26.88 [24.49, 29.63] | 27.45 [24.69, 30.39] | 0.20            | 26.76 [24.44, 29.41] | 26.95 [24.38, 29.76] | 0.88 |
| Prior MI | 132 (24.0)       | 213 (23.9)       | 1.00            | 82 (21.4)        | 131 (20.9)         | 0.90 |
| Prior CAGB | 15 (2.7)         | 24 (2.7)         | 1.00            | 13 (3.4)         | 15 (2.4)           | 0.45 |
| Prior PCI | 134 (24.5)       | 213 (23.9)       | 0.86            | 86 (22.5)        | 134 (21.4)         | 0.72 |
| Chronic renal failure | 23 (4.2)      | 49 (5.5)         | 0.33            | 20 (5.2)         | 44 (7.0)           | 0.31 |
| PVD | 33 (6.0)         | 35 (3.9)         | 0.09            | 24 (6.3)         | 26 (4.2)           | 0.18 |
| Prior CVA/TIA | 26 (4.7)      | 59 (6.6)         | 0.17            | 29 (7.6)         | 46 (7.4)           | 1.00 |
| History of CHF | 24 (4.4)     | 31 (3.5)         | 0.46            | 7 (1.8)          | 17 (2.7)           | 0.49 |
| Prior medications |                   |                   |                  |                  |
| Aspirin | 192 (35.2)       | 307 (36.6)       | 0.64            | 129 (33.9)       | 205 (35.0)         | 0.75 |
| Clopidogrel | 35 (6.4)         | 60 (7.4)         | 0.54            | 21 (5.5)         | 26 (4.8)           | 0.74 |
| ACE-I | 131 (24.1)       | 188 (23.8)       | 0.95            | 76 (19.9)        | 127 (23.6)         | 0.21 |
| ARB | 34 (6.2)         | 102 (14.1)       | <0.001          | 19 (5.0)         | 47 (9.8)           | 0.01 |
| Beta blockers | 140 (25.7)      | 207 (26.2)       | 0.89            | 86 (22.6)        | 116 (21.3)         | 0.71 |
| Statins | 204 (37.5)       | 329 (46.9)       | 0.001           | 132 (34.6)       | 219 (46.3)         | 0.001 |
| CCB | 83 (15.3)         | 140 (19.2)       | 0.07            | 51 (13.4)        | 70 (14.6)          | 0.68 |
| Nitrates | 27 (5.0)         | 14 (2.0)         | 0.005           | 7 (1.8)          | 7 (1.5)            | 0.87 |
| Hypoglycemic agents | 84 (15.3)    | 172 (19.3)       | 0.06            | 52 (13.5)        | 128 (20.4)         | 0.007 |
| Diuretics | 66 (12.0)        | 64 (8.8)         | 0.07            | 31 (8.1)         | 40 (8.4)           | 0.96 |

CAD = coronary artery disease, IQR = interquartile range, BMI = body mass index, MI = myocardial infarction, CAGB = coronary artery bypass graft surgery, PCI = percutaneous intervention, PVD = peripheral vascular disease, CVA = cerebral vascular accident, TIA = transient ischemic attack, CHF = congestive heart failure, ACE-I = Angiotensin-converting-enzyme inhibitor, ARB = Angiotensin II receptor blocker, CCB = calcium channel blockers.
The TIMI Coronary Grade Flow was initially established to ensure a uniform method of documenting epicardial perfusion on coronary arteriography. It has proven to be an effective clinical tool. Preprocedural TIMI grade flow has been shown to stratify patients at risk for increased MACE and mortality post STEMI [3,4,7]. Although the clinical outcomes of STEMI patients have improved throughout the years, the prognosis of these patients has not changed equally. Our first major finding was that the proportion of patients with TIMI flow grade 0 has remained unchanged while those with TIMI flow grade 3 has increased in the later period. The diagnosis of STEMI is the clinical representation of an acute occlusion of an epicardial coronary artery and thus it is not surprising that the majority of patients with STEMI have a TIMI flow grade of 0 at the time of catheterization. What is encouraging, is that the number of STEMI patients with TIMI flow grade 3 has increased over time. This suggests that while the electrocardiographic initial diagnosis is of acute coronary artery occlusion, there is a beneficial effect of the treatment given before the time of catheterization and as such the coronary flow seen at catheterization is improved. This finding is in contrast to the findings of the ATLANTIC trial, which showed that prehospital administration of ticagrelor in patients with STEMI did not improve pre-PCI coronary reperfusion. However, in the ATLANTIC trial cohort, the median time from symptoms onset to STEMI diagnosis and from randomization to angiography were 73 and 48 min respectively. These time delays reported are significantly shorter than in our real-world cohort and thus the effect of pre-hospital ticagrelor could have been blunted in this study [8]. The increasing availability and use of ECG-mobile devices may also be helpful tool in the early identification and thus improved outcomes of STEMI patients [9]. Further studies are needed to validate this.

We found that patients presenting with TIMI flow grade 0 still have poorer early clinical outcomes compared to those with TIMI flow grade 1-3 and this was still valid in the late period. This is consistent with findings of previous studies showing the poor prognosis associated with a lower TIMI flow grade [2,4]. Importantly, we found that the in-hospital complications of those with TIMI flow grade 0 has decreased over time. This is an encouraging finding which possibly suggests that the in-hospital management of these patients has improved. This could be due to improved primary PCI techniques, the use of newer-age stents and an increasing usage of radial access, as well as advances in evidence-based medical management and heart failure therapies available in later years [10,11]. Similar encouraging findings have been reported in other cohorts [12,13]. The 30-day MACE and 1-year mortality have not significantly changed over time with either subgroup of TIMI flow grade 0 or TIMI flow grade 1-3. This observation is probably multifactorial. Firstly, our findings did not show that the time from symptom onset to primary PCI did decrease over time. This delay is a surrogate for total ischemic time and is a major determinant of outcomes [14,15]. This delay is concerning and is due to both patient and system factors. This highlights the importance of public awareness of recognizing symptoms suggestion of myocardial infarction and accessing medical attention, as well as improving and encouraging collaboration between emergency services and cardiology services. Improvement in these aspects can assist in shortening this critical delay and thereby improving outcomes. Another explanation could be that of a survivor cohort effect. Patients who may have previously died prior to hospital transfer are benefitting and surviving due to improved advanced care in later years. However, these patients still have an increased mortality which could blunt the overall improved outcomes we would have expected in the later years. The lack of improved hard outcomes in our cohort could also be due to the size of our cohort as our results may be underpowered to detect meaningful differences in mortality.

To our knowledge this is the first study to assess temporal trends in TIMI flow grade and its effect on hard outcomes. We were able to assess this angiographic parameter and its prognostic impact in a real-world cohort, in an era in which dramatic changes have occurred in the management of patients with STEMI. Despite important advances in the management of these patients, our findings show that TIMI flow remains an important prognostic factor.

### 6. Study limitations

Our study has several limitations. Firstly, we did not have all the data on preprocedural TIMI flow grade for all STEMI patients in the ACSIS registry. Secondly, this study is an observational retrospective study with its inherent weaknesses. Thirdly, data regarding cardiac versus non-cardiac causes for mortality are not available, as well as data on the specific cause of death. Lastly, data on TIMI flow post the PCI are lacking, thus were not examined in the current study.
### Table 3
Angiography, In-hospital complications and laboratory tests over time periods of those with TIMI 0 vs TIMI 1-3.

|                  | TIMI 0                  |       | TIMI 1-3                 |       |
|------------------|-------------------------|-------|--------------------------|-------|
|                  | 2008–2010 | 2013–2018 | p value | 2008–2010 | 2013–2018 | p value |
| **n**            | 550     | 892      |         | 384     | 627      |         |
| **Angiography**  |         |          |         |         |          |         |
| Non-obstructive  | 6 (1.1) | 51 (5.9) | <0.001  | 4 (1.0) | 43 (7.1) | <0.001  |
| 1 Vessel Diseased| 214 (39.1) | 375 (43.1) | 145 (38.0) | 246 (40.6) |       |         |
| 2 Vessel Diseased| 188 (34.4) | 264 (30.3) | 136 (35.6) | 178 (29.4) |       |         |
| 3 Vessels Diseased| 139 (25.4) | 180 (20.7) | 97 (25.4) | 139 (22.9) |       |         |
| Left Anterior Descending | 266 (48.5) | 401 (45.2) | 0.34 | 177 (46.2) | 300 (48.4) | 0.13   |
| Circumflex Artery | 67 (12.2) | 121 (13.6) | 52 (13.6) | 93 (15.0) |       |         |
| Right Coronary Artery | 204 (37.2) | 347 (39.1) | 141 (36.8) | 216 (34.8) |       |         |
| Left Main        | 4 (0.7) | 4 (0.5)  | 4 (1.0) | 5 (0.8)  |         |         |
| Saphenous Vein Graft | 8 (1.5) | 8 (0.9)  | 4 (1.0) | 5 (0.8)  |         |         |
| Ramus            | 0 (0)   | 4 (0.5)  | 5 (1.3) | 0 (0)    |         |         |
| Other Graft      | 0 (0)   | 2 (0.2)  | 0 (0)   | 1 (0.2)  |         |         |
| Bare Metal Stent | 434 (78.1) | 139 (16.7) | <0.001 | 297 (85.1) | 121 (20.5) | <0.001 |
| Drug Eluting Stent | 86 (17.3) | 651 (78.4) | <0.001 | 64 (18.3) | 470 (79.5) | <0.001 |
| **In-hospital complications** |         |          |         |         |          |         |
| Composite of In-hospital complications | 197 (36.1) | 236 (26.8) | <0.001 | 89 (23.4) | 127 (20.3) | 0.28   |
| CHF mild-moderate (Killip Class II) | 58 (10.6) | 55 (6.2) | 0.004 | 24 (6.2) | 31 (5.0) | 0.46   |
| Pulmonary edema (Killip III) | 35 (6.4) | 29 (3.3) | 0.008 | 14 (3.6) | 23 (3.7) | 1.00   |
| Saphenous Vein Graft | 39 (7.1) | 52 (5.9) | 0.41 | 16 (4.2) | 21 (3.3) | 0.61   |
| Right Anterior Descending | 27 (4.9) | 13 (1.5) | <0.001 | 6 (1.6) | 1 (0.2) | 0.02   |
| CHF = congestive heart failure, MI = myocardial infarction, VSD = ventricular septal defect, MR = mitral regurgitation, VT = ventricular tachycardia, VF = ventricular fibrillation, CVA = cerebrovascular accident, CK = creatine kinase, IQR = interquartile range.

### Table 4
Treatment at discharge and at 30 day follow up over time periods of those with TIMI 0 vs TIMI 1-3.

|                  | TIMI 0                  |       | TIMI 1-3                 |       |
|------------------|-------------------------|-------|--------------------------|-------|
|                  | 2008–2010 | 2013–2018 | p value | 2008–2010 | 2013–2018 | p value |
| **n**            | 550     | 892      |         | 384     | 627      |         |
| **Treatment at discharge** |         |          |         |         |          |         |
| Aspirin          | 519 (96.5) | 840 (97.3) | 0.44 | 369 (97.4) | 606 (98.5) | 0.28   |
| P2Y12 Inhibitor  | 507 (94.2) | 600 (95.8) | 0.25 | 360 (95.0) | 386 (95.8) | 0.71   |
| **Type of P2Y12 Inhibitor during hospitalization or at discharge (%):** | <0.001 | <0.001 |         |         |          |         |
| Prasugrel        | 3 (0.6) | 527 (59.8) | 0 (0.0) | 335 (54.2) |         |         |
| Ticagrelor       | 0 (0.0) | 233 (26.4) | 0 (0.0) | 194 (31.4) |         |         |
| Clopidogrel      | 537 (99.4) | 122 (13.8) | 372 (100.0) | 89 (14.4) |         |         |
| Statin           | 507 (94.1) | 822 (97.0) | 0.01 | 359 (94.5) | 591 (97.5) | 0.02   |
| ACE-I/ARB        | 444 (82.4) | 717 (86.8) | 0.03 | 311 (81.8) | 515 (89.3) | 0.002  |
| Beta blocker     | 442 (82.2) | 708 (85.3) | 0.14 | 319 (84.2) | 494 (85.5) | 0.64   |
| Referral to cardiac rehabilitation | 319 (61.9) | 491 (68.8) | 0.01 | 225 (60.8) | 343 (67.8) | 0.03   |

ACE-I/ARB: Angiotensin-converting-enzyme inhibitor/Angiogenin II receptor blocker.
7. Conclusions

Preprocedural TIMI flow grade is still of prognostic significance in the current era. Patients with TIMI 0 have a poorer prognosis than their counterparts with TIMI 1–3. While in-hospital complications have decreased among patients with TIMI 0 over time, their 30-d MACE and 1-year mortality remained unchanged.

All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretations.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ijcha.2021.100868.

References

[1] J.E. Dalen, J.M. Gore, E. Braunwald, J. Borer, R.J. Goldberg, E.R. Passamani, et al., Six- and twelve-month follow-up of the phase I thrombolysis in myocardial infarction (TIMI) trial, Am. J. Cardiol. 62 (1988) 179–185, https://doi.org/10.1016/0002-9149(88)90208-1.

[2] G. De Luca, N. Ernst, F. Zijlstra, A.W.J. Van’t Hof, J.C.A. Hoorntje, J.H.E. Dambrink, et al., Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty, J. Am. College Cardiol. 43 (2004) 1363–1367, https://doi.org/10.1016/j.jacc.2003.11.042.

[3] G.W. Stone, D. Cox, E. Garcia, B.R. Brodie, M.-C. Morice, J. Griffin, et al., Normal Flow (TIMI-3) Before Mechanical Reperfusion Therapy Is an Independent Determinant of Survival in Acute Myocardial Infarction, Circulation 104 (2001) 636–641, https://doi.org/10.1161/01.cir.3101.093701.

[4] M.J. Schaff, N. Mewton, C. Rioufol, D. Angoulvant, G. Cayla, N. Delarche, et al., Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct...
size and microvascular obstruction in STEMI patients, J. Cardiol. 67 (2016) 248–253, https://doi.org/10.1016/j.jjcc.2015.05.008.

[5] T.B. Dondo, M. Hall, T. Munyombwe, C. Wilkinson, M.E. Yadegarfar, A. Timmis, et al., A nationwide causal mediation analysis of survival following ST-elevation myocardial infarction, Heart 106 (2020) 765–771, https://doi.org/10.1136/heartjnl-2019-315760.

[6] S. Garcia, C.W. Schmidt, R. Garbersich, T.D. Henry, S.M. Bradley, E.S. Brilakis, et al., Temporal changes in patient characteristics and outcomes in ST-segment elevation myocardial infarction 2003–2018, Catheteriz. Cardiovasc. Interventions (2020), https://doi.org/10.1002/ccd.28901.

[7] T. Bauer, U. Zeymer, A. Diallo, E. Vicaut, L. Bolognese, A. Cequier, et al., Impact of preprocedural TIMI flow on clinical outcome in low-risk patients with ST-elevation myocardial infarction: Results from the ATLANTIC study, Catheteriz. Cardiovasc. Interventions 95 (2020) 494–500, https://doi.org/10.1002/ccd.28318.

[8] G. Montalescot, A.W. van ‘t Hof, F. Lapostolle, J. Silvain, J.F. Lassen, L. Bolognese, et al., Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction, New Engl. J. Med. 371 (2014) 1016–1027. 10.1056/nejmoa1407024.

[9] S. Spaich, H. Kern, T.A. Zelniker, J. Stiepak, M. Gabel, E. Popp, et al., Feasibility of CardioSecur®, a Mobile 4-Electrode/22-Lead ECG Device, in the Prehospital Emergency Setting, Front. Cardiovasc. Med. (2020) 176, https://doi.org/10.3389/FCVM.2020.551796.

[10] M.V. Madhavan, A.J. Kirtane, B. Redfors, P. Généreux, O. Ben-Yehuda, T. Palmerini, et al., Stent-related adverse events >1 year after percutaneous coronary intervention, J. Am. Coll. Cardiol. 75 (2020) 590–604, https://doi.org/10.1016/j.jacc.2019.11.058.

[11] M. Valgimigli, A. Gagnor, P. Calabró, E. Frigoli, S. Leonardo, T. Zaro, et al., Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: A randomised multicentre trial, The Lancet 385 (2015) 2465–2476, https://doi.org/10.1016/S0140-6736(15)60292-6.

[12] C. García-García, T. Oliveras, J. Serra, J. Vila, F. Rueda, G. Cediel, et al., Trends in short- and long-term ST-segment-elevation myocardial infarction prognosis over 3 decades: A mediterranean population-based ST-segment-elevation myocardial infarction registry, J. Am. Heart Assoc. 9 (2020), https://doi.org/10.1161/JAHA.120.017155 e017159.

[13] B. Aliprandi-Costa, L. Morgan, L.C. Snell, D.M. Souza, L. Kritharides, J. French, et al., ST-elevation acute myocardial infarction in Australia—temporal trends in patient management and outcomes 1999–2016, Heart Lung Circulation 28 (2019) 1000–1008, https://doi.org/10.1016/j.hlc.2018.05.191.

[14] B.T. Squire, J.H. Tamayo-Sarver, P. Rashi, W. Koenig, J.T. Niemann, Effect of prehospital cardiac catheterization lab activation on door-to-balloon time, mortality, and false-positive activation, Prehospital Emergency Care 18 (2014) 1–8, https://doi.org/10.3109/10903127.2013.836263.

[15] R.K. Nallamothu, S.L.T. Normand, Y. Wang, T.P. Hofer, J.E. Brush, J.C. Messenger, et al., Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: A retrospective study, The Lancet 385 (2015) 1114–1122, https://doi.org/10.1016/S0140-6736(14)61932-2.